Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 16;39(35):4932-4937.
doi: 10.1016/j.vaccine.2021.07.007. Epub 2021 Jul 13.

COVID-19 vaccine capacity: Challenges and mitigation - The DCVMN perspective

Benoit Hayman  1 , Rajinder Suri  2 , Sai D Prasad  3
Affiliations

COVID-19 vaccine capacity: Challenges and mitigation - The DCVMN perspective

Benoit Hayman et al. Vaccine. .

Abstract

Vaccine manufacturers from developing countries have a proven track record of developing, producing, and supplying high-quality vaccines globally. However, due to the complexity of vaccine manufacturing, numerous stakeholder organizations support manufacturers across a variety of functions. To optimize the support from stakeholders it is instrumental to first understand which manufacturing processes these manufacturers require support for and what support functions are most beneficial. To this end, the Developing Countries Vaccine Manufacturers Network designed a comprehensive survey to assess the specific needs of the Network's member organizations. We found that almost all sampled manufacturers are interested in obtaining funding or technology transfers for COVID-19 vaccines. Furthermore, results indicated that manufacturers have a strong appetite for modern technology platforms, particularly RNA technologies. Scale-up, phase III clinical trials, and formulation were also key processes for which manufacturers require support.

Keywords: COVID-19; Clinical trials; Technology transfer; Vaccine supply.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Number of manufacturers interested in obtaining funding/technology support for the listed vaccine types. Respondents were able to select any number of vaccine types. Specific number of manufacturers for each vaccine type is indicated in parentheses. Four manufacturers selected ‘Other’ (Chikungunya, GBS, AMR, Cancer).
Fig. 2
Fig. 2
Number of sampled manufacturers who require support with the listed technology platforms (left) and the percentage of manufacturers who require each type of specific support (right). Respondents were able to select any number of technology platforms and support types. For technology platforms one manufacturer selected ‘Other’ (Conjugation Technology) and for type of support required two manufacturers selected ‘Other’ (Consultancy Support and Co-Development).
Fig. 3
Fig. 3
Matching Analysis - Number of manufacturers who can provide tech transfer and number who require tech transfer for the listed technology platforms. Respondents were able to select any number of technology platforms. For providing technology transfers six manufacturers selected ‘Other’ (Live Attenuated (4), Polysaccharide Subunit (1), Protein Subunit – For COVID-19 (1)).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Pagliusi, et al. Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply. Vaccine. 2020;38(34):5418–5423. doi: 10.1016/j.vaccine.2020.06.022. - DOI - PMC - PubMed
    1. World Health Organization: Prequalification. Available at https://extranet.who.int/pqweb/vaccines/prequalified-vaccines [accessed 20 April 2021].
    1. Hayman B., Pagliusi S. Emerging vaccine manufacturers are innovating for the next decade. Vaccine X. 2020 doi: 10.1016/j.jvacx.2020.100066. - DOI - PMC - PubMed
    1. World Health Organization: Draft landscape and tracker of COVID-19 candidate vaccines. Available at https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand... [accessed 20 April 2021].
    1. Plotkin, et al. The complexity and cost of vaccine manufacturing – an overview. Vaccine. 2017 doi: 10.1016/j.vaccine.2017.06.003. - DOI - PMC - PubMed